The relationship between SLC25A3 and primary mitochondrial disease was evaluated using the ClinGen Clinical Validity Framework as of July 24, 2023. The SLC25A3 gene encodes the solute carrier family 25 member 3 protein. This integral transmembrane protein acts as the major transporter of inorganic phosphate across the inner mitochondrial membrane, serving to maintain a pool of inorganic phosphate in the matrix for use in ATP synthesis.
SLC25A3 was first reported in relation to autosomal recessive primary mitochondrial disease in 2007 (PMID: 17273968), in two siblings with infantile onset hypertrophic cardiomyopathy, lactic acidosis, and hypotonia. While various names have been given to the constellation of features seen in those with SLC25A3-related disease, pathogenic variants in this gene cause a primary mitochondrial disease. Therefore, the SLC25A3 phenotype has been lumped into one disease entity according to the ClinGen Lumping and Splitting Framework.
Evidence supporting the gene-disease relationship between SLC25A3 and primary mitochondrial disease includes case-level data and experimental data. This curation includes four variants (two splice, one missense, one indel) in four probands across three publications (PMIDs: 17273968; 21763135; 25681081). Features seen in affected individuals include hypertrophic cardiomyopathy, developmental delay, exercise intolerance, hypotonia, and lactic acidosis. Mitochondrial respiratory chain enzyme activities in muscle were normal.
Loss of function is implicated as the mechanism of disease. This gene-disease relationship is also supported by known biochemical function and a conditional knock-out mouse model of SLC25A3 (PMIDs: 24658400; 33340416).
In summary, there is moderate evidence to support the relationship between SLC25A3 and autosomal recessive primary mitochondrial disease. While more evidence is needed to establish this relationship definitively, no convincing evidence has emerged that contradicts the gene-disease relationship. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Gene Curation Expert Panel on July 24, 2023 (SOP Version 9).
The GenCC data are available free of restriction under a CC0 1.0 Universal (CC0 1.0) Public Domain Dedication. The GenCC requests that you give attribution to GenCC and the contributing sources whenever possible and appropriate. The accepted Flagship manuscript is now available from Genetics in Medicine (https://www.gimjournal.org/article/S1098-3600(22)00746-8/fulltext).
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. The GenCC does not independently verify the submitted information. Though the information is obtained from sources believed to be reliable, no warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, reliability or usefulness of any information. This disclaimer applies to both isolated and aggregate uses of the information. The information is provided on an "as is" basis, collected through periodic submission and therefore may not represent the most up-to-date information from the submitters. If you have questions about the medical relevance of information contained on this website, please see a healthcare professional; if you have questions about specific gene-disease claims, please contact the relevant sources; and if you have questions about the representation of the data on this website, please contact gencc@thegencc.org.